Iceland· IS-EU/1/19/1405/002
TAVLESSE
A fostamatinib product containing fostamatinibum inn dínatríum hexahýdrat, registered in Iceland by Instituto Grifols S.A.*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Fostamatinib is registered in 13 of 19 countries.
Countries holding a registration under ATC B02BX09 (fostamatinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Fostamatinib · ATC B02BX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Fostamatinibum INN dínatríum hexahýdrat
- Manufacturer
- Instituto Grifols S.A.*
- Country
- Iceland (IS)
- ATC code
- B02BX09
- ATC class
- Fostamatinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean97363960 stk x1 pakkiISK 724083
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
545 interactions on record for fostamatinib.
Graded by severity as the source publishes them — 50 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fostamatinib · interactions on record
545 records
- 50 severe
- 493 moderate
- 2 minor
Most severe, free to view
- LonafarnibA16AX20severe
- BerotralstatB06AC06severe
- ConivaptanC03XA02severe
- MipomersenC10AX11severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fostamatinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTavlesse 150 mgInstituto Grifols
- CzechiaTAVLESSEInstituto Grifols, S.A., Barcelona
- SpainTAVLESSE 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULAInstituto Grifols S.A.
- FinlandTavlesseInstituto Grifols S.A.
- FranceTAVLESSE 150 mg, comprimé pelliculéINSTITUTO GRIFOLS
- IrelandTavlesse 150 mg film-coated tabletsInstituto Grifols S.A.
- NetherlandsTavlesse 150 mg filmomhulde tablettenInstituto Grifols S.A.
- NorwayTavlesseInstituto Grifols S.A
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Tavlesse
- Norway · Tavlesse
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b84c9c2b-9fb4-411a-a504-20c246515b54 GET /v1/drugs/b84c9c2b-9fb4-411a-a504-20c246515b54?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "B02BX09",
"marketed": false,
"strength": "150 mg",
"ma_number": "EU/1/19/1405/002",
"substance": "Fostamatinibum INN dínatríum hexahýdrat",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43839"
}See everything about fostamatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.